Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:PRME News 27 June 2025

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug WVE-006 showed proof-of-mechanism in humans in 2024, and multi-dose trial data are anticipated in 2025. In April 2025, the FDA approved Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for the rare skin disorder RDEB, with launch planned in Q3
27 June 2025
···········

Stock Market Today

National Grid share price on a six-session run: what could move NG.L when London reopens

National Grid share price on a six-session run: what could move NG.L when London reopens

8 February 2026
National Grid closed Friday at 1,285 pence, up 0.23%, marking its sixth straight gain and trading near a 52-week high. Investors focused on Bank of England survey results showing expectations for Bank Rate to fall to 3.0% by March 2027. UK GDP, trade, and industrial output data are due Feb. 12. 6.51 million National Grid shares changed hands in the session.
Idox share price stuck below 71.5p bid as Long Path says backing nears control

Idox share price stuck below 71.5p bid as Long Path says backing nears control

8 February 2026
Long Path Partners said it has aggregate support for about 49.26% of Idox shares for its 71.5p-per-share cash offer. Idox shares closed Friday at 71.0p, about 0.7% below the offer price. Valid acceptances stood at 19.12% as of Feb. 5, with the offer open until March 16. The deal requires more than 50% of voting rights to go unconditional.
BAE Systems share price: Buyback update and Launchpad incubator set up Feb 18 results

BAE Systems share price: Buyback update and Launchpad incubator set up Feb 18 results

8 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, with 5.6 million shares traded. The company disclosed buying back 115,039 shares for cancellation at a volume-weighted average price of 1,860.32 pence. Over 1,200 BAE workers in northwest England are striking over pay until at least Feb. 20. Full-year results are due Feb. 18.
Go toTop